Elevated H3K9me3 levels have two implications in cancer [36]: an increase in H3K9me3 levels in specific promoters is strongly associated with the suppression of tumor suppressor gene expression [37], and therefore inhibition of SUV39H1 or SETDB1 has been proposed as a promising therapeutic strategy in HCC [36, 38]. This evidence concerns the gene SUV39H1 and cancer.